RU2016147455A - Способ лечения кожных проявлений склеродермии - Google Patents
Способ лечения кожных проявлений склеродермии Download PDFInfo
- Publication number
- RU2016147455A RU2016147455A RU2016147455A RU2016147455A RU2016147455A RU 2016147455 A RU2016147455 A RU 2016147455A RU 2016147455 A RU2016147455 A RU 2016147455A RU 2016147455 A RU2016147455 A RU 2016147455A RU 2016147455 A RU2016147455 A RU 2016147455A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- scleroderma
- days
- skin manifestations
- daily
- Prior art date
Links
- 208000031709 Skin Manifestations Diseases 0.000 title claims 2
- 206010039710 Scleroderma Diseases 0.000 title 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 claims 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 1
- 201000003088 Limited Scleroderma Diseases 0.000 claims 1
- 208000024140 Limited cutaneous systemic sclerosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 1
- 229940004592 ganciclovir 250 mg Drugs 0.000 claims 1
- 229960000476 inosine pranobex Drugs 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (1)
- Способ лечения кожных проявлений как ограниченной, так и системной склеродермии, осуществляемый традиционным способом лечения, отличающийся тем, что дополнительно внутривенно вводится ганцикловир 250 мг на 100,0 мл физиологического раствора ежедневно в течение 12-15 дней, гроприносин (инозин пранобекс) по две таблетки три раза в день в течение 10 дней и тиоктовая кислота внутривенно или перорально по 600 мг ежедневно на протяжении 10 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2016147455A RU2657812C2 (ru) | 2016-12-02 | 2016-12-02 | Способ лечения кожных проявлений склеродермии |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2016147455A RU2657812C2 (ru) | 2016-12-02 | 2016-12-02 | Способ лечения кожных проявлений склеродермии |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016147455A3 RU2016147455A3 (ru) | 2018-06-05 |
| RU2016147455A true RU2016147455A (ru) | 2018-06-05 |
| RU2657812C2 RU2657812C2 (ru) | 2018-06-15 |
Family
ID=62557453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016147455A RU2657812C2 (ru) | 2016-12-02 | 2016-12-02 | Способ лечения кожных проявлений склеродермии |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2657812C2 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2716488C1 (ru) * | 2019-09-18 | 2020-03-13 | Государственное бюджетное учреждение Свердловской области "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ГБУ СО "УрНИИДВиИ") | Способ лечения бляшечной склеродермии |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2005488C1 (ru) * | 1992-06-16 | 1994-01-15 | Российская фармацевтическая компания "Фарма" | Средство для лечения болезней соединительной ткани |
| CN101049495A (zh) * | 2007-05-16 | 2007-10-10 | 北京艺信堂医药研究所 | 一种治疗硬皮病的中药制剂 |
-
2016
- 2016-12-02 RU RU2016147455A patent/RU2657812C2/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016147455A3 (ru) | 2018-06-05 |
| RU2657812C2 (ru) | 2018-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| MX2021002321A (es) | Nuevos metodos. | |
| SG10201901242PA (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| WO2016133903A3 (en) | Combination therapy for cancer treatment | |
| EA201591701A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| SG10201906400SA (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| FI3666258T3 (fi) | Menetelmä prader-willin oireyhtymän hoitamiseksi | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| MX2021002322A (es) | Nuevos metodos. | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| RU2016147455A (ru) | Способ лечения кожных проявлений склеродермии | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| BR112017025527A2 (pt) | preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| PH12015502560A1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181203 |